BPC-157 pentadecapeptide lyophilized vial — OMNIPOTENT ≥99% HPLC research compound — tendon and ligament research India

BPC-157 in Tendon & Ligament Research: Published Studies Reference (India 2026)

BPC-157 is the most-cited peptide in published preclinical research on tendon and ligament biology. The pentadecapeptide — derived from a partial sequence of a Body Protection Compound originally identified in gastric juice — has been studied in dozens of published animal-model and in-vitro tendon and ligament protocols. This 2026 reference summarises the published literature for India sports-medicine researchers, orthopaedic labs, and biohackers comparing the research-grade reference compound.

TL;DR

  • Compound: BPC-157, pentadecapeptide (15 amino acids), MW ~1,419 Da, CAS 137525-51-0
  • Most-cited research areas: rat Achilles tendon transection models, rat medial collateral ligament (MCL) models, in-vitro tenocyte and ligament-cell studies
  • Published in-vivo observations: referenced effects on tendon healing kinetics, collagen organisation, and tensile strength recovery in animal models
  • Research-grade reference: OMNIPOTENT BPC-157 — 10 mg lyophilised vial, ₹9,499, HPLC ≥99%, batch COA

Tenocyte biology — quick context

Tendons and ligaments are dense connective tissues dominated by type I collagen organised into highly aligned fibrils. The cell type is the tenocyte — a specialised fibroblast that synthesises and maintains the collagen-rich ECM. Key features in published research:

  • Slow turnover — tendon collagen has a half-life of decades
  • Poor vascularisation — limited blood supply, which contributes to slow healing in injury
  • Mechanical loading drives adaptation — anabolic mechanotransduction
  • Injury produces scar-like type III collagen healing rather than full type I regeneration in many published animal models

Compounds that can shift the healing pattern toward better type I organisation are of significant research interest — which is where BPC-157 enters the picture.

Published animal-model tendon research

The most-cited preclinical BPC-157 tendon research uses rat Achilles tendon transection models. Published features:

  • Sikiric and colleagues published multiple foundational papers in the 1990s–2010s on BPC-157 and rat Achilles tendon healing
  • Published observations: referenced faster tendon healing kinetics, improved biomechanical (tensile-strength) recovery, and improved collagen-organisation histology compared with control
  • Reported dosing in these published rat models: typically 10 µg/kg or 10 ng/kg administered intraperitoneally or applied locally to the surgical site
  • Time-courses studied: typically 14, 21, and 28 days post-injury

These are animal-model observations from published peer-reviewed literature. They are research observations, not clinical recommendations.

Published research: medial collateral ligament (MCL) and other ligaments

Beyond the Achilles tendon literature, published BPC-157 research has extended to:

  • Rat medial collateral ligament transection models
  • Quadriceps tendon and patellar tendon protocols
  • Limited cruciate ligament research
  • Some published research on bone-tendon interface (enthesis) healing

The breadth of published animal-model healing research is part of why BPC-157 has accumulated such a large body of citations in the orthopaedic and sports-medicine research literature.

Published in-vitro tenocyte research

In addition to animal models, published in-vitro research has examined BPC-157 effects on cultured tenocytes:

  • Cell proliferation and migration assays
  • VEGF-related angiogenic-marker expression
  • Effects on collagen type I and type III gene expression
  • FAK (focal adhesion kinase) and growth-factor receptor pathway studies

The published mechanistic hypothesis combines effects on angiogenic signalling, growth-factor receptor expression, and ECM gene regulation — a multi-pathway picture rather than a single-target one.

BPC-157 and clinical translation — what's published vs what's claimed

The gap between published preclinical research and clinical evidence in humans is important to acknowledge:

  • Published preclinical: Hundreds of peer-reviewed animal-model and in-vitro studies on multiple tissues
  • Published clinical: Very limited — small case series, mostly without rigorous control arms; one published clinical trial in inflammatory bowel disease at the gastric-injury research interface
  • Regulatory status: Not approved by CDSCO, the US FDA, the EMA, or any other regulator for any therapeutic use

BPC-157 may be sold and purchased in India strictly as a chemical reference standard for in-vitro laboratory research — not as a therapeutic. See our India peptide regulatory guide.

Combinatorial research with TB-500 and KLOW

BPC-157 is frequently studied in combination with TB-500 (Thymosin Beta-4 fragment) in published research — the two are considered the most-cited "healing peptide" pairing. The KLOW 4-in-1 blend co-formulates both alongside GHK-Cu and KPV in a single lyophilised vial, designed for combinatorial research protocols.

See our TB-500 vs BPC-157 comparison for the detailed mechanism-and-sourcing contrast.

India research lab use cases

  • In-vitro tenocyte and ligament-cell studies: Using rat or human tenocyte primary cultures or established lines
  • Analytical method development: HPLC and LC-MS protocols for BPC-157 quantification in formulation work
  • Stability studies: Characterising peptide degradation under Indian-climate stress
  • Combinatorial in-vitro work: BPC-157 paired with TB-500 or GHK-Cu on wound-healing models

Storage, reconstitution, India considerations

  • Pre-reconstitution: Sealed vial 2–8 °C, protected from light
  • Reconstitution: Bacteriostatic Water (0.9% benzyl alcohol)
  • Reconstitution example: 10 mg vial + 5 ml BAC water = 2 mg/ml stock
  • Post-reconstitution: Refrigerated (2–8 °C), protected from light, used within documented stability window
  • India climate: Critical to refrigerate immediately on arrival in Indian summer (35–45 °C ambient)

India price benchmarks 2026 — BPC-157

  • Fair INR range, 5 mg: ₹5,500 – ₹9,000
  • Fair INR range, 10 mg: ₹8,500 – ₹14,000
  • OMNIPOTENT 10 mg: ₹9,499 | with 10 ml BAC water: ₹11,098

FAQ

Does BPC-157 "heal tendons"?
The published animal-model literature observes referenced effects on tendon healing kinetics and tensile-strength recovery. Translation to clinical tendon healing in humans is not supported by published large-scale clinical trial evidence. We make no therapeutic claim.

What's the most-cited BPC-157 tendon paper?
The Sikiric group's published work on rat Achilles tendon transection models from the 1990s–2010s is the most-cited foundational reference. Subsequent papers extend to MCL, patellar tendon, and other tissues.

Can I source BPC-157 for in-vitro tenocyte research in India?
Yes — OMNIPOTENT BPC-157 dispatches from within India in sealed lyophilised vials, HPLC ≥99%, with batch-specific COA on request.

Should I buy BPC-157 alone or in the KLOW blend?
For standalone BPC-157 studies, the 10 mg vial; for combinatorial protocols with TB-500, GHK-Cu, and KPV, the KLOW blend is more economical per peptide.

Related research peptides and articles

Disclaimer: Research-literature reference only. BPC-157 is supplied strictly as a chemical reference standard for in-vitro laboratory research. Not approved by CDSCO or any other regulator. References to published animal-model observations are research observations, not therapeutic claims.

Back to blog